Retatrutide

Retatrutide

Retatrutide (also known as Retatrutide acetate or LY3437943) is an investigational once-weekly injectable triple agonist developed by Eli Lilly that simultaneously targets GLP-1, GIP, and glucagon receptors — the broadest mechanistic profile among current investigational weight loss and metabolic peptides. Licensed practitioners interested in buying Retatrutide can contact Medical Spa Rx’s professional support team for guidance on sourcing from qualified suppliers and for access to supporting documentation, including purity information. This page provides an overview of Retatrutide and its research applications through the sections and FAQ below.

Retatrutide Dosing, Before & After: Phase 2 Efficacy Data

Retatrutide is an investigational GLP-1/GIP/glucagon receptor triple agonist developed by Eli Lilly and studied for obesity, overweight with metabolic comorbidities, and type 2 diabetes. It is not approved by the FDA, EMA, or TGA for clinical prescribing outside authorized trial settings. All efficacy claims are tied to published trial data rather than approved prescribing guidance. (Current as of June 2026.)

Phase 2 Efficacy: Retatrutide Before and After

The primary published efficacy data come from a Phase 2 randomized, double-masked, placebo-controlled trial by Jastreboff and colleagues, published in the New England Journal of Medicine in June 2023. The study enrolled 338 adults with obesity or overweight with at least one weight-related comorbidity (excluding type 2 diabetes) and evaluated once-weekly subcutaneous Retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg over 48 weeks.

Mean body weight reductions at week 48 [1]:

• 1 mg: approximately 8.7%
• 4 mg: approximately 17.1%
• 8 mg: approximately 22.8%
• 12 mg: approximately 24.2%
• Placebo: approximately 2.1%

The highest-dose weight-loss curves had not clearly plateaued by week 48, suggesting that longer Phase 3 data will be needed to fully characterize the response trajectory. In a cross-trial context, the 12 mg result exceeded published benchmarks for Semaglutide 2.4 mg in STEP-1 and Tirzepatide 15 mg in SURMOUNT-1, though these are not head-to-head comparisons, and differences in trial design, population, and duration should be considered.

Phase 3 TRIUMPH Program

The TRIUMPH Phase 3 program is ongoing [2]. TRIUMPH-1 topline results were announced in May 2026, reporting approximately 28.3% mean body weight reduction at 12 mg over 80 weeks; full peer-reviewed publication is pending. A separate late-stage diabetes trial, TRANSCEND-T2D-1, reported positive results in March 2026, showing approximately 16.8% weight loss at 40 weeks alongside clinically meaningful reductions in HbA1c [4]. Until Phase 3 findings are fully published and reviewed, Retatrutide should be framed as a compelling investigational signal awaiting full regulatory evaluation.

Retatrutide and Menopausal Weight Gain

No dedicated randomized controlled trial has evaluated Retatrutide specifically in peri- or postmenopausal populations. While the triple-agonist mechanism, which encompasses appetite regulation, energy expenditure, and adipose tissue biology, may be mechanistically relevant to weight management in this population, menopause-specific claims should not be made until dedicated subgroup or clinical trial data are available.

Retatrutide Mechanism of Action: GLP-1, GIP & Glucagon Triple Agonism

Retatrutide targets three receptor pathways, each addressing a distinct metabolic bottleneck [3]. Combined activation produces body weight reductions exceeding those of dual agonism in Phase 2 data, with all three pathways converging on improved glycemic control and insulin sensitivity in type 2 diabetes and insulin-resistance contexts.

GLP-1 Receptor Agonism

• Appetite suppression and satiety signaling through hypothalamic and brainstem GLP-1 receptor pathways
• Slowed gastric emptying via vagal signaling
• Glucose-dependent insulin secretion from pancreatic beta cells
• The same core pathway targeted by Semaglutide; in Retatrutide, GLP-1R activity is one component of a broader triple-agonist mechanism

GIP Receptor Agonism

• Adds a second incretin signal supporting glucose-dependent insulin secretion alongside GLP-1R activity
• May contribute to adipose tissue insulin sensitivity, lipid handling, and anti-inflammatory signaling
• Forms the same dual GLP-1/GIP framework as Tirzepatide; Retatrutide extends this by adding glucagon receptor activity

Glucagon Receptor Agonism: The Key Differentiator

• Supports hepatic fatty acid oxidation, reduced de novo lipogenesis, and hepatic lipid export
• May increase energy expenditure through brown adipose thermogenesis and FGF21-related pathways
• Introduces a thermogenic and liver-fat-focused mechanism absent from both GLP-1-only and GLP-1/GIP dual agonism
• Although glucagon receptor activation can increase hepatic glucose output, Retatrutide’s GLP-1R and GIPR activity may offset this through insulinotropic and insulin-sensitizing effects

Retatrutide Dosing: How Long Will 10mg Last & BAC Water Reconstitution

Retatrutide dosing in the Phase 2 trial used once-weekly subcutaneous injections with gradual escalation to target doses of 4 mg, 8 mg, or 12 mg. No FDA-approved dosing protocol exists outside authorized clinical trial settings. All figures below are trial-derived.

At once-weekly dosing, a 10 mg vial corresponds to one dose at that dose level. Total supply depends on the titration schedule, target maintenance dose, and protocol duration. Practitioners should calculate supply requirements against the specific trial or research protocol in use.

Bacteriostatic water is the standard reference for reconstitution in research and practitioner discussions. As a common example, adding 2 mL of BAC water to a 10 mg vial yields a concentration of 5 mg/mL. Final concentration, injection volume, and handling should follow institutional procedures and product-specific documentation. No universally validated reconstitution protocol exists outside authorized trial formulations.

Storage

Refrigerated at 2–8°C; protect from light; use within the stability window specified by the manufacturer, pharmacy, or supplier documentation.

Retatrutide Side Effects, Safety & Legal Status

Based on Phase 2 safety data, Retatrutide’s adverse event profile was broadly consistent with GLP-1 receptor agonist-containing therapies. No unexpected safety signals were reported, but long-term safety data remain incomplete while Phase 3 studies continue.

Commonly reported and potential side effects:

• Gastrointestinal effects (most common): nausea, vomiting, diarrhea, and constipation; generally mild to moderate and managed through gradual dose escalation
• Pancreatitis risk: class-level risk for all GLP-1 receptor agonists applies; unexplained persistent abdominal pain should be monitored during titration
• Hair loss: telogen effluvium secondary to rapid caloric deficit and weight loss, not a direct pharmacological drug effect; typically transient and resolves with stabilized weight
• Elevated resting heart rate: possible through glucagon receptor activity; relevant in research subjects with cardiovascular risk factors

Current Regulatory Status

As of mid 2026, Retatrutide is not approved by the FDA, EMA, or TGA for any indication. It remains investigational and is available only in authorized clinical trial settings while the Phase 3 TRIUMPH program continues [2]. Currently approved weight-loss alternatives include Tirzepatide and Semaglutide, which remain the evidence-based standards of care outside research or trial settings. All regulatory details are subject to change/

Retatrutide vs Tirzepatide & Retatrutide vs Semaglutide

Tirzepatide is an FDA-approved dual GLP-1/GIP receptor agonist (Mounjaro/Zepbound), while Retatrutide adds a third pathway through glucagon receptor agonism — contributing increased energy expenditure, brown adipose thermogenesis, hepatic fatty acid oxidation, and liver fat reduction that Tirzepatide does not directly address. Cross-trial Phase 2 data show a mean body weight reduction of approximately 24% with Retatrutide 12 mg at 48 weeks [1], compared with approximately 21% with Tirzepatide 15 mg in SURMOUNT-1 [5], though differences in trial design, population, and duration make a direct comparison inappropriate. Tirzepatide retains the decisive advantages of regulatory approval, an established prescribing protocol, and a larger clinical safety record. Practitioners who buy Tirzepatide as their dual-agonist standard of care are working within the current evidence-based framework, where the clinical significance of adding the glucagon receptor will depend on what the full Phase 3 Retatrutide data show.

Semaglutide (Ozempic/Wegovy) is a selective GLP-1 receptor agonist, making it the largest mechanistic step down from Retatrutide’s triple-agonist profile. The addition of GIP and glucagon receptor activity in Retatrutide introduces adipose tissue effects, glucagon receptor-mediated thermogenesis, and hepatic lipid handling that are entirely absent from GLP-1 monotherapy. Phase 2 data show an approximately 24% reduction in mean body weight with Retatrutide 12 mg at 48 weeks [1], exceeding the STEP-1 benchmark of approximately 15% with Semaglutide 2.4 mg — though again, not head-to-head. Practitioners who buy Semaglutide for established GLP-1 protocols benefit from its post-marketing safety record and cardiovascular outcomes data, advantages that Retatrutide cannot yet match while Phase 3 TRIUMPH publication remains pending.

Where Can Practitioners Buy Retatrutide for Research?

Retatrutide is available for research purposes only to qualified licensed professionals. Practitioners evaluating sourcing for Retatrutide should work exclusively with suppliers that provide verifiable purity documentation, including a certificate of analysis (COA), LOT number traceability, and clear handling and storage specifications. Those looking to check for wholesale buying options should confirm that any supplier meets these documentation standards and that procurement complies with jurisdiction-specific regulations, given Retatrutide’s investigational status.

Medical Spa Rx’s professional support team offers sourcing guidance and access to supporting documentation for licensed practitioners evaluating research-grade Retatrutide. For guidance on supplier qualification, purity records, and compliance considerations, contact the professional support team directly.

FAQs

1. What is Retatrutide?

Retatrutide (also known as Retatrutide acetate or LY3437943) is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors [3], developed by Eli Lilly. It is currently in Phase 3 clinical development under the TRIUMPH program. Phase 2 data published in the New England Journal of Medicine in 2023 reported mean body weight reduction of approximately 24.2% at 48 weeks with the 12 mg dose [1]. Retatrutide is not FDA-approved and is classified as investigational only.

2. Is Retatrutide FDA approved?

No. As of June 2026, Retatrutide is not approved by the FDA, EMA, or TGA for any indication. It remains limited to authorized clinical trial settings while Phase 3 TRIUMPH studies continue [2]. Currently approved weight-loss alternatives include Tirzepatide and Semaglutide. Regulatory status is subject to change; practitioners should verify current requirements before procurement or protocol consideration.

3. Is Retatrutide safe?

Phase 2 data suggest a safety profile consistent with GLP-1 receptor agonist-containing therapies, with no unexpected safety signals reported in the published trial [1]. Gastrointestinal effects — nausea, vomiting, diarrhea, and constipation — were the most common adverse events. Long-term safety data remain incomplete pending completion of Phase 3 and peer-reviewed publication.

4. What are the Retatrutide side effects?

The most commonly reported Phase 2 side effects were gastrointestinal, including nausea, vomiting, diarrhea, and constipation [1]. A class-level pancreatitis risk applies because of the GLP-1R component. Hair loss associated with rapid weight loss is more accurately described as telogen effluvium rather than a direct drug effect. Elevated resting heart rate may also occur through glucagon receptor activity.

5. How long will 10mg of Retatrutide last?

At once-weekly dosing, a 10 mg vial corresponds to one dose at that dose level. Total supply depends on the titration schedule, target maintenance dose, and protocol duration. Because Retatrutide has no FDA-approved dosing schedule, all supply calculations should remain protocol-specific and trial-derived.

6. How much BAC water for 10mg Retatrutide?

A common reference calculation is to add 2 mL of bacteriostatic water to a 10 mg vial, yielding a 5 mg/mL concentration. Final reconstitution volume should depend on the desired concentration, injection volume, formulation, and institutional handling procedures. No universally validated Retatrutide reconstitution protocol exists outside authorized trial formulations.

7. Where can practitioners buy Retatrutide?

Licensed professionals evaluating where to buy Retatrutide wholesale should prioritize verified purity documentation, supplier qualification, and jurisdiction-specific compliance. Medical Spa Rx’s professional support team can provide guidance on sourcing from qualified suppliers and access to supporting documentation, including certificates of analysis. Retatrutide remains investigational and is not approved for clinical prescribing outside authorized trial settings.

Sources

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
2. GLP-3 Wiki. Retatrutide Clinical Trials & FDA Timeline Tracker. https://www.glp3.wiki/trials
3. Eli Lilly Medical. Retatrutide-Diabetes. Updated October 6, 2025. https://medical.lilly.com/us/products/answers/what-is-the-mechanism-of-action-of-retatrutide-301926
4. Constantino AK. Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial. CNBC. Published March 19, 2026. https://www.cnbc.com/2026/03/19/eli-lillys-obesity-drug-retatrutide-clears-late-stage-diabetes-trial.html
5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.